A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia.

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Aripiprazole lauroxil (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Alkermes plc
  • Most Recent Events

    • 19 Sep 2017 Results of post-hoc subgroup analysis from parent (EudraCT2012-003445-15) and their extension (EudraCT2012-003996-20) studies published in the Journal of Clinical Psychiatry
    • 30 Aug 2016 Results published in the Journal of Clinical Psychiatry (2016).
    • 28 Mar 2016 Data from this trial will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top